Back to top
more

Exact Sciences (EXAS)

(Delayed Data from NSDQ)

$69.80 USD

69.80
2,470,028

+0.87 (1.26%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $69.80 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

DexCom (DXCM) Q1 Earnings and Revenues Surpass Estimates

DexCom's (DXCM) first-quarter earnings benefit from solid segmental performance.

Is a Beat in Store for Avadel (AVDL) This Earnings Season?

On Avadel's (AVDL) Q1 earnings call, investor focus will be on the company's lead candidate, FT218, currently being evaluated to treat excessive daytime sleepiness and cataplexy in narcolepsy patients.

What's in Store for Unum Therapeutics' (UMRX) Q1 Earnings?

During Unum Therapeutics' (UMRX) upcoming Q1 earnings call, investor focus will be on the company's progress pertaining to its preclinical program, BOXR1030, for treating solid tumor cancers.

Ecolab (ECL) Q1 Earnings and Revenues Surpass Estimates

Strength in the Global Industrial and Institutional segments drives Ecolab's (ECL) first-quarter results.

Henry Schein (HSIC) to Report Q1 Earnings: What's in Store?

Contribution from Henry Schein's (HSIC) medical business in the form of point-of-care antibody rapid test is likely to have boosted Q1 performance amid the coronavirus pandemic.

What's in Store for Aytu BioScience's (AYTU) Q3 Earnings?

On Aytu BioScience's (AYTU) upcoming earnings call, investor focus will be on its distribution right to commercialize the COVID-19 IgG/IgM Rapid Test in North America.

Novavax (NVAX) to Report Q1 Earnings: What's in the Cards?

During Novavax's (NVAX) upcoming Q1 earnings call, investor focus will be on the company's progress with its seasonal influenza vaccine candidate, NanoFlu, and the COVID-19 vaccine candidate.

Is a Beat in Store for Abeona (ABEO) This Earnings Season?

Abeona's (ABEO) operating expenses are expected to have increased in the first quarter driven by clinical studies on its lead gene therapy candidate.

What's in Store for IDEXX Laboratories (IDXX) in Q1 Earnings?

IDEXX's (IDXX) business is likely to have benefited from few cases in which pets were found to be COVID-19 positive globally.

Can IC and PI Arms Drive Boston Scientific (BSX) Q1 Earnings?

Boston Scientific's (BSX) business trends in the first two months of the quarter in line with its expectations.

Illumina (ILMN) to Report Q1 Earnings: What's in the Offing?

Illumina (ILMN) is upbeat about its first-quarter sequencing consumable revenue growth.

ResMed (RMD) Q3 Earnings to Gain From Growing Ventilator Sales

ResMed (RMD) is expected to have gained from increased adoption of flagship products and a ramped-up ventilator production capacity in Q3 amid the coronavirus pandemic.

Align Technology (ALGN) to Report Q1 Earnings: What's in Store?

Align Technology (ALGN) is expected to have gained from continued adoption of Invisalign system in the first two months of Q1.

Can Diagnostics Aid Hologic (HOLX) Q2 Sales Amid Coronavirus?

Strength in segmental businesses is likely to have aided Hologic's (HOLX) performance in second-quarter fiscal 2020 amid the coronavirus-led economic doldrums.

Exact Sciences (EXAS) Stock Sinks As Market Gains: What You Should Know

Exact Sciences (EXAS) closed at $60.89 in the latest trading session, marking a -0.56% move from the prior day.

Exact Sciences Grows on New Deals, Down on Coronavirus Scare

Exact Sciences (EXAS) progressing well in terms of the company's three priorities.

Exact Sciences (EXAS) Gains But Lags Market: What You Should Know

In the latest trading session, Exact Sciences (EXAS) closed at $42.47, marking a +0.14% move from the previous day.

Exact Sciences (EXAS) Down 39.7% Since Last Earnings Report: Can It Rebound?

Exact Sciences (EXAS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Sriparna Ghosal headshot

Genetic Test Gets Okayed by FDA: 4 Stocks to Keep an Eye On

The growth in genetic testing market can be attributed to factors like rise in incidence of genetic disorders, cancer and technological breakthroughs.

Kevin Cook headshot

Bull of the Day: Guardant Health (GH)

Cancer diagnostics provider who delivered 181% revenue growth and 18,500 tests to patients and labs partners with Amgen

Exact Sciences (EXAS) Q4 Earnings and Revenues Rise Y/Y

Exact Sciences' (EXAS) fourth-quarter 2019 results reflect strong segmental performances.

Tracey Ryniec headshot

5 Earnings All-Stars with Spectacular Charts

These 5 companies have near perfect earnings surprise track records and their charts are a sight to behold.

Benjamin Rains headshot

Should Growth Investors Buy this Cancer Screening Biotech Stock?

Exact Sciences is the biotech firm behind the popular at-home colon cancer screening test, Cologuard. So is EXAS stock worth considering for growth investors?

Exact Sciences (EXAS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Exact Sciences (EXAS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

What's in the Cards for Exact Sciences' (EXAS) Q4 Earnings?

Exact Sciences' (EXAS) Q4 performance is likely to have benefited from developments in business segments.